Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 12:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 401 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: oral fat Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

NCT06502379
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD8965, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 8, 2026, 12:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparing the Effects of Exercise on the Structure and Function of Fat Tissue

NCT05328570
View directory record Official record
Conditions
Adiposity
Interventions
Oral Glucose Tolerance Test
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 8, 2026, 12:27 PM EDT
Completed Not applicable Interventional Results available

Eplerenone in HIV Associated Abdominal Fat Accumulation

NCT01405456
View directory record Official record
Conditions
HIV
Interventions
Eplerenone and lifestyle, placebo and lifestyle
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 8, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

NCT05630677
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD5055 solution for infusion, AZD5055 oral suspension, AZD5055 film-coated tablet, Rabeprazole, Delayed-release tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 8, 2026, 12:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Fructose Intestinal Gluconeogenesis

NCT07209202
View directory record Official record
Conditions
Healthy Participants, Obese But Otherwise Healthy Participants
Interventions
High fructose meal, Low fructose meal, 13C labeled fructose, oral, 13C labeled fructose, intravenous
Other
Lead sponsor
Touro University, California
Other
Eligibility
20 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Vallejo, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 8, 2026, 12:27 PM EDT
Not yet recruiting Phase 2 Interventional

Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity

NCT07572175
View directory record Official record
Conditions
Anthracycline-induced Cardiotoxicity, Lymphoma, Chemotherapy, Cardiotoxicity
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 8, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.

NCT06385119
View directory record Official record
Conditions
Healthy Participants
Interventions
Plixorafenib, Cobicistat
Drug
Lead sponsor
Fore Biotherapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 8, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects

NCT01129271
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, Matching placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2011 · Synced Sep 8, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

NCT04839809
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-92480, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 8, 2026, 12:27 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440

NCT03890341
View directory record Official record
Conditions
Healthy
Interventions
Drospirenone/Ethinylestradiol, Midazolam, JNJ-64530440
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 8, 2026, 12:27 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

NCT06980428
View directory record Official record
Conditions
Healthy Participants, Dyslipidemia
Interventions
AZD4954, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 8, 2026, 12:27 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy Adults

NCT07731100
View directory record Official record
Conditions
Healthy Adults
Interventions
Prifetrastat
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 8, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654

NCT06389955
View directory record Official record
Conditions
Healthy
Interventions
TP 3654
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 8, 2026, 12:27 PM EDT
Withdrawn Phase 2 Interventional

Vitamin E Efficacy in HI/HA

NCT04984798
View directory record Official record
Conditions
Hyperinsulinism-Hyperammonemia Syndrome
Interventions
Vitamin E
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 8, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62

NCT05409027
View directory record Official record
Conditions
Type 2 Diabetes Mellitus in Obese, Obesity, Type2Diabetes
Interventions
SPI-62, Cortisone-d8
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Sep 8, 2026, 12:27 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Stromal Vascular Fraction for Treatment of Xerostomia

NCT03061110
View directory record Official record
Conditions
Xerostomia Due to Radiotherapy (Disorder)
Interventions
Stromal Vascular Fraction, Usual Care
Biological · Other
Lead sponsor
Midwestern Regional Medical Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 8, 2026, 12:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

NCT01794520
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Venetoclax, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
21
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 8, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

NCT02536391
View directory record Official record
Conditions
Cancer
Interventions
Ipatasertib (capsule), Ipatasertib (tablet)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 8, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of CMS121, a Drug Candidate for Alzheimer's Disease, in Healthy Subjects

NCT05318040
View directory record Official record
Conditions
Alzheimer Disease
Interventions
CMS121, Placebo
Drug
Lead sponsor
Virogenics, Inc.
Industry
Eligibility
19 Years to 85 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 8, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

NCT05767905
View directory record Official record
Conditions
Healthy
Interventions
PF-06821497 Treatment A, PF-06821497 Treatment B, PF-06821497 Treatment C, PF-06821497 Treatment D, PF-06821497 Treatment E, PF-06821497 Treatment F
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 8, 2026, 12:27 PM EDT
Completed Not applicable Interventional Results available

Exercise and Pioglitazone for HIV-Metabolic Syndromes

NCT00639457
View directory record Official record
Conditions
HIV Infections, Type 2 Diabetes, Obesity, HIV, AIDS, Cardiovascular Disease, Lipodystrophy
Interventions
Pioglitazone, Exercise training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Sep 8, 2026, 12:27 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Apolipoprotein E (APOE) Genotype Effects on Triglycerides and Blood Flow in the Human Brain

NCT04692441
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Heavy Cream
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 8, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Repeated Dose Escalation Study of GSK2838232

NCT02795754
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232 PIB, GSK2838232 IR1, GSK2838232 IR2, Placebo PIB, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 8, 2026, 12:27 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

NCT04128293
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254 Tablet, GSK3640254 Capsule
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Sep 8, 2026, 12:27 PM EDT